ReviewClinical microbiology reviews2021
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection.
Review in Clinical microbiology reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 5 syntheses or guidelines pooled it, 215 citations in OpenAlex.
- Kikuchi-Fujimoto in the light of the COVID-19: infection and vaccination. A systematic review.Clinical rheumatology · 2025Pooled it
- Anticoagulation in COVID-19 patients - An updated systematic review and meta-analysis.Thrombosis research · 2022Pooled it
- A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.International journal of biological sciences · 2022Pooled it
- Follow-Ups on Persistent Symptoms and Pulmonary Function Among Post-Acute COVID-19 Patients: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- The Predictive Value of Myoglobin for COVID-19-Related Adverse Outcomes: A Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- Safety, Tolerability, Bioavailability, and Biological Activity of Inhaled Interferon-α2b in Healthy Adults: The INClinical drug investigation · 2023Trial
- Comparative analysis of clinically approved lipid nanoparticles for intranasal siRNA delivery against SARS-CoV-2.Drug delivery and translational research · 2026Article
- Sex-Specific Association of Toll-like Receptor 8 Polymorphisms with COVID-19 Case Status in a Korean Population.Life (Basel, Switzerland) · 2026Article
- Temperature and developmental stage govern intestinal susceptibility to human coronavirus 229E.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Amplifying immune responses via a parenteral prime-intranasal boost strategy using a lipidated chitosan nanoparticle-based multi-epitope COVID-19 vaccine.Scientific reports · 2026Article
- Covid-19 a Strong Predictor of Hyperglycaemia Among Ugandan Patients: A Retrospective Study.Research square · 2026Article
- Activated immune cells present a lung interstitial-to-airway/alveolar cross-compartment sharing pattern in severe pneumonia.Clinical and translational medicine · 2026Article
- Comparison of SARS-CoV-2 variant pathogenicity in a long-COVID Syrian hamster model.Virus research · 2026Article
- Multi-Strain Probiotic Intervention Modestly Modulates Microbial Composition and Inflammatory Profile in Individuals with Long COVID.Microorganisms · 2026Article
- Simple and high-containment lung-on-chip model for studying respiratory viral infections using human primary lung cells.Materials today. Bio · 2025Article
- A survey of SARS-CoV-2 tropism.Infectious diseases & immunity · 2025Review
- Changes in Placentas of Pregnant Women Infected with COVID-19.International journal of molecular sciences · 2025Article
- A comparative analysis of clinical characteristics between primary and recurrent COVID-19 infections in China.Infectious medicine · 2025Article
- Longitudinal alterations of gut mycobiota during 2 years after COVID-19 and its correlation with pulmonary sequela.Microbiology spectrum · 2025Article
- Long-Term Clinical Outcomes of Adults Hospitalized for COVID-19 Pneumonia.Emerging infectious diseases · 2025Observational
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, seven identified coronaviruses (CoVs) have been found to infect humans; of these, three highly pathogenic variants have emerged in the 21st century. The newest member of this group, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first detected at the end of 2019 in Hubei province, China. Since then, this novel coronavirus has spread worldwide, causing a pandemic; the respiratory disease caused by the virus is called coronavirus disease 2019 (COVID-19). The clinical presentation ranges from asymptomatic to mild respiratory tract infections and influenza-like illness to severe disease with accompanying lung injury, multiorgan failure, and death. Although the lungs are believed to be the site at which SARS-CoV-2 replicates, infected patients often report other symptoms, suggesting the involvement of the gastrointestinal tract, heart, cardiovascular system, kidneys, and other organs; therefore, the following question arises: is COVID-19 a respiratory or systemic disease? This review aims to summarize existing data on the replication of SARS-CoV-2 in different tissues in both patients and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.